The Experts below are selected from a list of 45 Experts worldwide ranked by ideXlab platform

Philippe Lanotte - One of the best experts on this subject based on the ideXlab platform.

  • Detection of Bartonella in cat scratch disease using a single-step PCR Assay Kit
    Journal of Medical Microbiology, 2017
    Co-Authors: C. Hobson, C. Le Brun, Clémence Beauruelle, Z. Maakaroun-vermesse, Laurent Mereghetti, A. Goudeau, Philippe Lanotte
    Abstract:

    Purpose. Bartonella is an increasingly isolated emerging pathogen that can cause severe illness in humans, including cat scratch disease (CSD). The bacteria are difficult to grow and thus many detection methods have been developed, especially molecular. We previously developed a PCR method targeting ribC to identify Bartonella sp. A manufactured Kit (RealCycler BART, Progenie Molecular) was commercialised shortly thereafter for the detection of Bartonella infection, including Bartonella henselae. Methodology. We performed a comparison between this test and our in-house PCR Assay on 73 lymphadenopathy samples sent to the laboratory for suspicion of CSD. Results/Key findings. Among the 28 positive samples for Bartonella, 21 were identified by the two PCR Assays, and seven by the commercial Kit only. Conclusion. The performance of this commercial Kit suggests that it could be a suitable alternative to our in-house PCR Assay, highlighting the importance of the molecular methods used to diagnose

C. Hobson - One of the best experts on this subject based on the ideXlab platform.

  • Detection of Bartonella in cat scratch disease using a single-step PCR Assay Kit
    Journal of Medical Microbiology, 2017
    Co-Authors: C. Hobson, C. Le Brun, Clémence Beauruelle, Z. Maakaroun-vermesse, Laurent Mereghetti, A. Goudeau, Philippe Lanotte
    Abstract:

    Purpose. Bartonella is an increasingly isolated emerging pathogen that can cause severe illness in humans, including cat scratch disease (CSD). The bacteria are difficult to grow and thus many detection methods have been developed, especially molecular. We previously developed a PCR method targeting ribC to identify Bartonella sp. A manufactured Kit (RealCycler BART, Progenie Molecular) was commercialised shortly thereafter for the detection of Bartonella infection, including Bartonella henselae. Methodology. We performed a comparison between this test and our in-house PCR Assay on 73 lymphadenopathy samples sent to the laboratory for suspicion of CSD. Results/Key findings. Among the 28 positive samples for Bartonella, 21 were identified by the two PCR Assays, and seven by the commercial Kit only. Conclusion. The performance of this commercial Kit suggests that it could be a suitable alternative to our in-house PCR Assay, highlighting the importance of the molecular methods used to diagnose

Shinya Kimura - One of the best experts on this subject based on the ideXlab platform.

  • A new highly sensitive real-time quantitative-PCR method for detection of BCR-ABL1 to monitor minimal residual disease in chronic myeloid leukemia after discontinuation of imatinib
    2019
    Co-Authors: Hiroaki Kitamura, Yoko Tabe, Koji Tsuchiya, Maiko Yuri, Shigeki Misawa, Takashi Horii, Akimichi Ohsaka, Atsushi Kawaguchi, Shinya Kimura
    Abstract:

    Tyrosine kinase inhibitors (TKIs) targeting the BCR-ABL1 fusion protein, encoded by the Philadelphia chromosome, have drastically improved the outcomes for patients with chronic myeloid leukemia (CML). Although several real-time quantitative polymerase chain reaction (RQ-PCR) Kits for the detection of BCR-ABL1 transcripts are commercially available, their accuracy and efficiency in laboratory practice require reevaluation. We have developed a new in-house RQ-PCR method to detect minimal residual disease (MRD) in CML cases. MRD was analyzed in 102 patients with CML from the DOMEST study, a clinical trial to study the rationale for imatinib mesylate discontinuation in Japan. The BCR-ABL1/ABL1 ratio was evaluated using the international standard (IS) ratio, where IS < 0.1% was defined as a major molecular response. At enrollment, BCR-ABL1 transcripts were undetectable in all samples using a widely-applied RQ-PCR method performed in the commercial laboratory, BML (BML Inc., Tokyo, Japan); however, the in-house method detected the BCR-ABL1 transcripts in five samples (5%) (mean IS ratio: 0.0062 ± 0.0010%). After discontinuation of imatinib, BCR-ABL1 transcripts were detected using the in-house RQ-PCR in 21 patients (21%) that were not positive using the BML method. Nineteen samples were also tested using a commercially available RQ-PCR Assay Kit with a detection limit of IS ratio, 0.0032 (ODK-1201, Otsuka Pharmaceutical Co., Tokyo, Japan). This method detected low levels of BCR-ABL1 transcripts in 14 samples (74%), but scored negative for five samples (26%) that were positive using the in-house method. From the perspective of the in-house RQ-PCR method, number of patients confirmed loss of MMR was 4. These data suggest that our new in-house RQ-PCR method is effective for monitoring MRD in CML.

  • A new highly sensitive real-time quantitative-PCR method for detection of BCR-ABL1 to monitor minimal residual disease in chronic myeloid leukemia after discontinuation of imatinib
    2018
    Co-Authors: Yoko Tabe, Hiroaki Kitamura, Koji Tsuchiya, Maiko Yuri, Shigeki Misawa, Takashi Horii, Akimichi Ohsaka, Shinya Kimura
    Abstract:

    Tyrosine kinase inhibitors (TKIs) targeting the BCR-ABL1 fusion protein, encoded by the Philadelphia chromosome, have drastically improved the outcomes for patients with chronic myeloid leukemia (CML). Although several real-time quantitative polymerase chain reaction (RQ-PCR) Kits for the detection of BCR-ABL1 transcripts are commercially available, their accuracy and efficiency in laboratory practice require reevaluation. We have developed a new in-house RQ-PCR method to detect minimal residual disease (MRD) in CML cases. MRD was analyzed in 102 patients with CML from the DOMEST study, a clinical trial to study the rationale for imatinib mesylate discontinuation in Japan. The BCR-ABL1/ABL1 ratio was evaluated using the international standard (IS) ratio, where IS < 0.01% was defined as a major molecular response. At enrollment, BCR-ABL1 transcripts were undetectable in all samples using a widely-applied RQ-PCR method performed in the commercial laboratory, BML (BML Inc., Tokyo, Japan); however, the in-house method detected the BCR-ABL1 transcripts in five samples (5%) (mean IS ratio: 0.0062 {+/-} 0.0010%). After discontinuation of imatinib, BCR-ABL1 transcripts were detected using the in-house RQ-PCR in 21 patients (21%) that were not positive using the BML method. Nineteen samples were also tested using a commercially available RQ-PCR Assay Kit with a detection limit of IS ratio, 0.0007% (ODK-1201, Otsuka Pharmaceutical Co., Tokyo, Japan). This method detected low levels of BCR-ABL1 transcripts in 14 samples (74%), but scored negative for five samples (26%) that were positive using the in-house method. These data suggest that our new in-house RQ-PCR method is effective for monitoring MRD in CML.

C. Le Brun - One of the best experts on this subject based on the ideXlab platform.

  • Detection of Bartonella in cat scratch disease using a single-step PCR Assay Kit
    Journal of Medical Microbiology, 2017
    Co-Authors: C. Hobson, C. Le Brun, Clémence Beauruelle, Z. Maakaroun-vermesse, Laurent Mereghetti, A. Goudeau, Philippe Lanotte
    Abstract:

    Purpose. Bartonella is an increasingly isolated emerging pathogen that can cause severe illness in humans, including cat scratch disease (CSD). The bacteria are difficult to grow and thus many detection methods have been developed, especially molecular. We previously developed a PCR method targeting ribC to identify Bartonella sp. A manufactured Kit (RealCycler BART, Progenie Molecular) was commercialised shortly thereafter for the detection of Bartonella infection, including Bartonella henselae. Methodology. We performed a comparison between this test and our in-house PCR Assay on 73 lymphadenopathy samples sent to the laboratory for suspicion of CSD. Results/Key findings. Among the 28 positive samples for Bartonella, 21 were identified by the two PCR Assays, and seven by the commercial Kit only. Conclusion. The performance of this commercial Kit suggests that it could be a suitable alternative to our in-house PCR Assay, highlighting the importance of the molecular methods used to diagnose

Clémence Beauruelle - One of the best experts on this subject based on the ideXlab platform.

  • Detection of Bartonella in cat scratch disease using a single-step PCR Assay Kit
    Journal of Medical Microbiology, 2017
    Co-Authors: C. Hobson, C. Le Brun, Clémence Beauruelle, Z. Maakaroun-vermesse, Laurent Mereghetti, A. Goudeau, Philippe Lanotte
    Abstract:

    Purpose. Bartonella is an increasingly isolated emerging pathogen that can cause severe illness in humans, including cat scratch disease (CSD). The bacteria are difficult to grow and thus many detection methods have been developed, especially molecular. We previously developed a PCR method targeting ribC to identify Bartonella sp. A manufactured Kit (RealCycler BART, Progenie Molecular) was commercialised shortly thereafter for the detection of Bartonella infection, including Bartonella henselae. Methodology. We performed a comparison between this test and our in-house PCR Assay on 73 lymphadenopathy samples sent to the laboratory for suspicion of CSD. Results/Key findings. Among the 28 positive samples for Bartonella, 21 were identified by the two PCR Assays, and seven by the commercial Kit only. Conclusion. The performance of this commercial Kit suggests that it could be a suitable alternative to our in-house PCR Assay, highlighting the importance of the molecular methods used to diagnose